艾德生物
(300685)
| 流通市值：84.16亿 | | | 总市值：85.22亿 |
| 流通股本：3.94亿 | | | 总股本：3.99亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 233,288,808.06 | 1,043,506,694.32 | 707,591,539.73 | 458,706,418.67 |
| 营业收入 | 233,288,808.06 | 1,043,506,694.32 | 707,591,539.73 | 458,706,418.67 |
| 二、营业总成本 | 167,788,210.58 | 743,673,780.47 | 522,953,544.65 | 325,528,824.4 |
| 营业成本 | 36,257,584.57 | 167,293,960.37 | 116,030,378.92 | 75,153,229.78 |
| 税金及附加 | 791,514.8 | 4,671,686.63 | 2,960,931.54 | 2,050,433.15 |
| 销售费用 | 65,440,315.27 | 329,493,879.54 | 222,940,761.68 | 144,376,585 |
| 管理费用 | 20,199,068.62 | 64,846,632.32 | 52,789,664.56 | 35,260,493.03 |
| 研发费用 | 48,363,080.43 | 203,217,283.53 | 150,754,888.33 | 91,866,703.87 |
| 财务费用 | -3,263,353.11 | -25,849,661.92 | -22,523,080.38 | -23,178,620.43 |
| 其中:利息费用 | 306,922.67 | 1,195,078.85 | 846,795.84 | 649,692.3 |
| 其中:利息收入 | 6,135,144 | 19,169,576.79 | 13,166,395.54 | 8,456,886.34 |
| 加:公允价值变动收益 | 2,616,462.72 | 8,394,360.75 | 5,158,149.13 | 3,407,446.03 |
| 加:投资收益 | -220,268.16 | -10,393,975.1 | -6,152,197.24 | -4,461,459.23 |
| 资产处置收益 | 50,535.06 | -959,584.98 | -907,320.44 | -5,446.71 |
| 资产减值损失(新) | 5,008.05 | -13,524,302.99 | 140,187.53 | 270,263.82 |
| 信用减值损失(新) | 775,665.58 | -5,315,987.25 | -6,405,785.6 | -4,303,906.91 |
| 其他收益 | 6,219,563.96 | 23,213,292.59 | 20,133,168.47 | 16,874,165.91 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 74,947,564.69 | 301,246,716.87 | 196,604,196.93 | 144,958,657.18 |
| 加:营业外收入 | 34,048.01 | 123,031.32 | 486,312.52 | 399,907.85 |
| 减:营业外支出 | 1,415,388.36 | 6,512,623.63 | 3,531,180.07 | 1,755,823.09 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 73,566,224.34 | 294,857,124.56 | 193,559,329.38 | 143,602,741.94 |
| 减:所得税费用 | 9,367,156.31 | 33,372,691.19 | 19,825,927.19 | 16,841,502.07 |
| 六、净利润 | 64,199,068.03 | 261,484,433.37 | 173,733,402.19 | 126,761,239.87 |
| 持续经营净利润 | 64,199,068.03 | 261,484,433.37 | 173,733,402.19 | 126,761,239.87 |
| 归属于母公司股东的净利润 | 64,199,068.03 | 261,484,433.37 | 173,733,402.19 | 126,761,239.87 |
| 少数股东损益 | - | - | - | 0 |
| (一)基本每股收益 | 0.16 | 0.66 | 0.44 | 0.32 |
| (二)稀释每股收益 | 0.16 | 0.66 | 0.44 | 0.32 |
| 八、其他综合收益 | - | 602,856.41 | -300,612.36 | 545,061.37 |
| 归属于母公司股东的其他综合收益 | - | 602,856.41 | -300,612.36 | 545,061.37 |
| 九、综合收益总额 | 64,199,068.03 | 262,087,289.78 | 173,432,789.83 | 127,306,301.24 |
| 归属于母公司股东的综合收益总额 | 64,199,068.03 | 262,087,289.78 | 173,432,789.83 | 127,306,301.24 |
| 归属于少数股东的综合收益总额 | - | - | - | 0 |
| 公告日期 | 2024-04-23 | 2024-04-16 | 2023-10-24 | 2023-08-01 |
| 审计意见(境内) | | 标准无保留意见 | | |